Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.

Lin CH, Chen CC, Wong J, McIntyre RS.

J Affect Disord. 2014 Jun;161:123-6. doi: 10.1016/j.jad.2014.02.039. Epub 2014 Mar 13.

PMID:
24751319
2.

Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.

Lin CH, Yen YC, Chen MC, Chen CC.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:93-8. doi: 10.1016/j.pnpbp.2013.08.003. Epub 2013 Aug 27.

PMID:
23989033
3.

The relationship between symptom relief and functional improvement during acute fluoxetine treatment for patients with major depressive disorder.

Lin CH, Chou LS, Chen MC, Chen CC.

J Affect Disord. 2015 Aug 15;182:115-20. doi: 10.1016/j.jad.2015.04.022. Epub 2015 Apr 22.

PMID:
25985380
4.

Comparison of physician-rating and self-rating scales for patients with major depressive disorder.

Lin CH, Lu MJ, Wong J, Chen CC.

J Clin Psychopharmacol. 2014 Dec;34(6):716-21. doi: 10.1097/JCP.0000000000000229.

PMID:
25310200
5.

Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.

Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.

Psychiatry Clin Neurosci. 2011 Aug;65(5):510-7. doi: 10.1111/j.1440-1819.2011.02235.x.

6.

The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.

Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE.

Int Clin Psychopharmacol. 2005 Mar;20(2):87-91.

PMID:
15729083
7.

Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.

Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, Nierenberg AA, Fava M.

J Clin Psychopharmacol. 2004 Oct;24(5):507-11.

PMID:
15349006
8.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
9.

A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.

Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF.

J Clin Psychopharmacol. 2005 Oct;25(5):441-7.

PMID:
16160619
10.

Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes.

Lin CH, Huang CJ, Liu SK.

Psychiatry Res. 2016 Apr 30;238:368-373. doi: 10.1016/j.psychres.2015.11.009. Epub 2015 Nov 23.

PMID:
26899817
11.

Pain has a strong negative impact on the fluoxetine response in hospitalized patients with major depressive disorder.

Lin CH, Lane HY, Chen CC, Juo SH, Yen CF.

Clin J Pain. 2011 Nov-Dec;27(9):805-10. doi: 10.1097/AJP.0b013e3182201849.

PMID:
21677571
12.

Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.

Lin HS, Wang FC, Lin CH.

J Clin Psychopharmacol. 2015 Dec;35(6):661-6. doi: 10.1097/JCP.0000000000000410.

PMID:
26479220
13.

Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.

Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM.

Psychosom Med. 2000 Nov-Dec;62(6):783-9.

PMID:
11138997
14.

Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.

Cassano P, Soares CN, Cusin C, Mascarini A, Cohen LS, Fava M.

Psychother Psychosom. 2005;74(6):362-5.

PMID:
16244512
15.

A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.

Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J.

Int Clin Psychopharmacol. 2008 Sep;23(5):269-75. doi: 10.1097/YIC.0b013e328301a74c.

PMID:
18703936
16.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA.

J Clin Psychiatry. 2002 Mar;63(3):225-31.

PMID:
11926722
17.

Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.

Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI.

Int Clin Psychopharmacol. 2010 Jul;25(4):214-7. doi: 10.1097/YIC.0b013e328339fbbd.

18.

Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.

Small GW, Birkett M, Meyers BS, Koran LM, Bystritsky A, Nemeroff CB.

J Am Geriatr Soc. 1996 Oct;44(10):1220-5.

PMID:
8856002
19.

Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.

Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M.

J Clin Pharm Ther. 2005 Apr;30(2):133-8.

PMID:
15811165
20.

Supplemental Content

Support Center